HER2-Positive Gastric Adenocarcinoma — Trials

HER2-Positive Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 6
Ph III recruiting: 2
Growth YoY: —
Industry share: 40%
Top sponsor: Qilu Hospital of Shandong University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04602117	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer	withdrawn	Phase 1	0	QuantumLeap Healthcare CollaborativeOTHER	1	Nov 18, 2023	clinicaltrials
NCT04464967	Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers	withdrawn	Phase 1 / Phase 2	0	NKGen Biotech, Inc.INDUSTRY	0	May 12, 2021